Can Rifaximin (Xifaxan) Be Used as Long-Term Therapy?
Yes, rifaximin can and should be used as long-term therapy for secondary prophylaxis of hepatic encephalopathy in patients with cirrhosis who have experienced recurrent overt episodes. The evidence demonstrates both safety and efficacy with continuous use extending beyond 24 months.
Guideline-Based Recommendations
Primary Indication for Long-Term Use
Rifaximin 550 mg twice daily is recommended as long-term secondary prophylaxis following more than one episode of overt hepatic encephalopathy within 6 months of the first episode 1, 2. This represents a Grade 2+ recommendation with strong agreement from both EASL (2022) and French (2023) guidelines.
The treatment algorithm is:
- First episode of overt HE: Start lactulose as secondary prophylaxis 1
- Second episode within 6 months: Add rifaximin 550 mg twice daily to lactulose 1, 2
- Continue indefinitely unless liver function improves significantly and precipitating factors are controlled 1
Alternative Scenarios
When lactulose is poorly tolerated, rifaximin can be used as monotherapy for preventing HE recurrence, though this is based on expert opinion rather than high-quality evidence 2.
Safety Profile with Long-Term Use
FDA-Documented Long-Term Safety
The FDA label documents extensive long-term safety data: 348 patients received rifaximin 550 mg, with 265 exposed for 6 months and 202 exposed for more than one year (mean exposure 364 days) 3. The continuation of open-label treatment for more than 24 months showed good safety profile with continued efficacy 2.
Adverse Events
Common adverse events (≥5%) in long-term use include peripheral edema (15%), nausea (14%), dizziness (13%), and fatigue (12%), but discontinuation rates due to adverse reactions were low (6% vs 4% placebo) 3. No serious treatment-related adverse events were observed in long-term studies 4.
Clinical Benefits of Long-Term Therapy
Beyond HE Prevention
Long-term rifaximin administration (up to 36 months) provides multiple benefits:
- Progressive decrease in blood ammonia levels maintained over time 4
- Improvement in Child-Pugh scores and hepatic functional reserve 5, 4
- Reduction in hospitalizations and improved quality of life 2
- Potential improvement in refractory ascites (36.5% of patients) 4
- Reduced risk of infections (IRR 0.64,95% CI 0.47-0.89) 6
Predictive Factors
Patients with elevated C-reactive protein levels (>0.69 mg/dL) at baseline are more likely to experience improvement in liver functional reserve with long-term rifaximin 5.
Important Caveats and Monitoring
Antibiotic Resistance Concern
A critical 2025 study revealed that 67% of patients on long-term rifaximin developed high-level rifaximin-resistant E. coli compared to 12% of controls 7. While this may not affect rifaximin's efficacy for HE prevention (since the drug acts locally in the gut), it could potentially limit its utility for preventing spontaneous bacterial peritonitis. This represents an emerging concern that warrants monitoring but does not currently contraindicate long-term use for HE prevention.
Severe Hepatic Impairment
Exercise caution in Child-Pugh C cirrhosis due to increased systemic absorption 3. Clinical trials were limited to patients with MELD scores <25, and only 9% were Child-Pugh Class C 3. However, long-term studies in Japanese populations showed that while Child C patients had shorter survival, there was no significant difference compared to controls not receiving rifaximin 8.
When to Consider Discontinuation
Discontinuation of rifaximin should be considered on an individual basis only when 1:
- Liver function has significantly improved
- Nutritional status has improved
- Precipitating factors have been controlled
- This is a weak recommendation (77% consensus)
Contraindications to Long-Term Use
Do not use rifaximin long-term in:
- Patients with current overt HE who have not achieved remission (treat acute episode first)
- Patients with known hypersensitivity to rifaximin or rifamycin antimicrobials 3
Practical Implementation
Standard dosing: Rifaximin 550 mg orally twice daily, continued indefinitely 1, 2
Concomitant therapy: 91% of patients in pivotal trials used lactulose concurrently 3. Continue lactulose titrated to 2-3 bowel movements daily 1.
No dose adjustment needed for renal impairment or mild-moderate hepatic impairment, though systemic exposure increases with severity of liver disease 3.